1. Home
  2. Live Updates
  3. Yusri elsayed

Live Breaking News & Updates on Yusri Elsayed

Stay updated with breaking news from Yusri elsayed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Johnson & Johnson : advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA

Media contacts:




Investor contact:




. ....

South Korea , United States , Yusri Elsayed , Biljana Naumovic , Christie Corbett , Satu Glawe , European Hematology Association , Oncologic Drugs Advisory Committee , National Comprehensive Cancer Network , Legend Biotech United States Inc , Drug Administration , Janssen Biotech Inc , A Us National Healthcare Claims Analysis , Janssen Pharmaceuticals , European Myeloma Network , European Commission , European Medicines Agency , American Society Of Clinical Oncology , Astex Pharmaceuticals , Clinical Oncology , Annual Meeting , Global Therapeutic Head , Johnson Innovative , Solid Tumor , Oral Abstract , Poster Abstract ,

Johnson & Johnson procures Ambrx Biopharma to Develop Oncology Portfolio

#industry #news #UK #2024 #insights #zenopa #recruitment #Johnson #Johnson #Ambrx #Biopharma #Oncology #Portfolio #acquired #platform #prostate #cancer ....

Ambrx Biopharma , Yusri Elsayed ,

Golden Cross Alert: Johnson & Johnson Shines With Ambrx Deal, Bullish Technical Signal - Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson stock down 1.22% in 6 months, up 5.57% in a year, and 3% YTD. Recent acquisition of Ambrx Biopharma boosts stock. Golden Cross signals trend reversal. ....

Yusri Elsayed , Ambrx Biopharma , Golden Cross , Global Therapeutic Area Head , Johnson Innovative , Insights Into Johnson , Performance Versus Peers In Pharmaceuticals , Cross On The Technical Charts Signals ,

Johnson & Johnson to acquire Ambrx Biopharma

The acquisition will advance next generation antibody drug conjugates to transform the treatment of cancer. ....

Ambrx Biopharma , Margaret Yu , Yusri Elsayed , Johnson Innovative ,

Johnson & Johnson to Acquire Ambrx for $2 Billion

The acquisition strengthens Johnson & Johnson's oncology portfolio. ....

Yusri Elsayed , Margaret Yu , Scripps Research Institute , Ambrx Biopharma Inc , Global Therapeutic , Prostate Cancer Disease , Biologics License Application , New Drug Application , Plus Lazertinib ,